Prot #CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent or In Combination With Ciforadenant, with Pembrolizumab, And With Ciforadenant Plus Pembrolizumab In Adult Subjects With Advanced Ca

Project: Research project

StatusActive
Effective start/end date12/20/1912/20/22

Funding

  • Corvus Pharmaceuticals, Inc. (Prot #CPI-006-001)